Pfizer and Valneva Begins Phase 3 Trial of Lyme Disease Vaccine


Pfizer Inc. and Valneva has announced the beginning of a Phase 3 clinical study of Vaccine Against Lyme for Outdoor Recreationists (VALOR), to investigate the safety, efficacy, and immunogenicity of the investigational Lyme disease vaccine candidate known as VLA15.

Annaliesa Anderson, senior vice president and head of vaccine research and development at Pfizer, said with increasing rates across the globe of Lyme disease, providing a new option for people to help protect themselves from the disease is very important.  Annaliesa Anderson also said they hope that the generated from the Phase 3 study will support the positive evidence for VLA15 to date, and they are also looking forward to partner with the research sites across Europe and the United States on trial.

Juan Carlos Jaramillo, chief medical officer of Valneva, said they are pleased to reach this important milestone in the development of VLA15. The Lyme disease continues to spread, and represent a high unmet medical need that impacts the lives of many people in the Northern Hemisphere.

READ  AstraZeneca: Preliminary Data Shows Third Covid-19 Shot Helps Against Omicron Variant

Juan Carlos Jaramillo said they look forward to further investigate the VLA15 candidate in Phase 3 study, which will take them a step closer to potentially bringing the vaccine to both children and adults who will benefit from it.